← Companies
Company
Frequency Therapeutics
Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.
Programs
2
linked to organization
Strong Evidence
0
2 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
2 / 0
industry vs non-industry records
Competitive Density
3
Pipeline Velocity
0
Completion Signal
0
Programs by Stage
Phase 11
Phase 21
Trial / Program Status
Discontinued2
Modality Mix
Regenerative Medicine2
Indication Coverage
Hearing Loss2
Sensorineural Hearing Loss2
Noise-Induced Hearing Loss1
Sudden Sensorineural Hearing Loss1
Program Types
Therapeutic2
Population Tags
adult2
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksFX-322 by Frequency Therapeutics
Status confirmed
Regenerative MedicinePhase 2Discontinued
Intratympanic small-molecule combination was designed to activate cochlear progenitor cells and regenerate sensory cells needed for hearing.
FX-345 by Frequency Therapeutics
Status confirmed
Regenerative MedicinePhase 1Discontinued
Second-generation intratympanic small-molecule regenerative program designed for broader cochlear exposure than FX-322.